Creative Medical Technologies Licenses Patient-Specific Adult Stem Cell Therapy for Male Infertility
Clinical Stage Adult Stem Cell Company Expands Portfolio of Clinical Indications
Creative Medical Technologies, Inc. (CMT) announced today the signing of a license agreement with LA BioMed granting exclusive rights for United States patent application # 14/508763, covering the use of stem cells for treatment of male infertility. In the patent application and a subsequent publication, Ronald S. Swerdloff, M.D., an LA BioMed lead researcher and UCLA professor of medicine, demonstrated that the administration of bone marrow cells into the testicles of mice with chemically induced damage to sperm producing cells led to the generation of new sperm-producing cells. In order to specifically demonstrate that the cells that were produced originated from the donor bone marrow, the team used genetically engineered mice possessing Green Fluorescent Protein (GFP) in every cell of their body. Interestingly, mice that did not have GFP possessed sperm-producing cells that were green after they had received intra-testicular administration of GFP bone marrow.
“We are extremely excited about the potential utilization of simple, autologous (from the same patient) bone marrow stem cells for the treatment of a condition that possesses a devastating social and economic toll on members of our society who are affected by it,” said Timothy Warbington, Chief Executive Officer of Creative Medical Technologies. “The investment bank Harris Williams reports that infertility represents a $3 to $4 billion dollar a year market, currently comprised of fertility drugs and assisted reproductive technologies. While infertility affects 15% of couples, according to a publication authored by the Cleveland Clinic, male infertility accounts for 30 to 40% of cases.”
Subsequent to filing the patent and the original publication, numerous international scientific groups have reproduced the finding that bone marrow derived stem cells are capable of giving rise to sperm generating cells.,,,. [L1]
Thomas Ichim, Ph.D, President of Creative Medical Technologies, stated: “The broadest claim of this patent provides the potential for an incredible intellectual property fence surrounding the field of male reproductive failure and stem cells.”
The patent claim says: “A method of treating infertility and/or testosterone deficiency in a male mammal, said method comprising: implanting stem cells into the testes of said mammal whereby said stem cells differentiate into germ cells and/or Sertoli cells and/or Leydig cells thereby reducing infertility and/or testosterone deficiency.”
Creative Medical Technologies plans to accelerate clinical development of the patent application by leveraging its clinical expertise in the area of autologous bone marrow cell therapies, in part gained from its ongoing clinical trial utilizing this approach for treatment of erectile dysfunction, which is covered in its patent # 8,372,797.
“This agreement with CMT is the latest in LA BioMed's ongoing work to transform today's research into tomorrow's cures,” said David Meyer, Ph.D, LA BioMed President and CEO. “We are very pleased to be working with CMT and other companies to bring new therapies, medical devices and healthcare solutions to patients around the world.”
 Lue et al. Am J Pathol. 2007 Mar; 170(3): 899–908. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1864883/
 Tamadon et al. Int J Stem Cells. 2015 Nov;8(2):134-45. http://www.ncbi.nlm.nih.gov/pubmed/26634062
 Zhang et al. Int J Mol Sci. 2014 Jul 24;15(8):13151-65. http://www.ncbi.nlm.nih.gov/pubmed/25062349
 Aghamir et al. Urology. 2014 Jul;84(1):82-6. http://www.ncbi.nlm.nih.gov/pubmed/24797037
 Drusenheimer et al. Soc Reprod Fertil Suppl. 2007;63:69-76. http://www.ncbi.nlm.nih.gov/pubmed/17566262
[L1]No commas needed; one footnote with the four citations contained in that footnote might work better? .